Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8079753 | 0.70 | LMNA (0.42) | SIGMAR1LMNACYP2C9SLC6A4SLC6A3 | |
| SCHEMBL14298073 | 0.70 | LMNA (0.42) | SIGMAR1LMNACYP2C9SLC6A4SLC6A3 | |
| SCHEMBL10156397 | 0.69 | LMNA (0.40) | SIGMAR1LMNACYP2C9SLC6A4SLC6A3 | |
| SCHEMBL21216586 | 0.69 | LMNA (0.40) | SIGMAR1LMNACYP2C9SLC6A4SLC6A3 | |
| SCHEMBL4743604 | 0.69 | LMNA (0.46) | SIGMAR1LMNACYP2C9SLC6A4SLC6A3 | |
| SCHEMBL22032235 | 0.69 | GRM5 (0.31) | — | |
| SCHEMBL13676319 | 0.67 | — | — | |
| SCHEMBL278331 | 0.67 | — | — | |
| SCHEMBL24474071 | 0.67 | — | — | |
| SCHEMBL357366 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585877-B2 | Aminophenyl derivatives as selective androgen receptor modulators | ACADIA PHARMACEUTICALS, INC. | 2009-09-08 | — | — | US | disclosed |
| US-7268232-B2 | Androgen receptor modulators and method of treating disease using the same | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | ACADIA PHARMACEUTICALS INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004679-A1 | Androgen receptor modulators and methods of treating disease using the same | NR5A1, AR, ESRRA | SIGMAR1 812/4885LMNA 2903/4885CYP2C9 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.